IDEAYA Biosciences names new chief medical officer
29 November 2022 -

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a US-based synthetic lethality focused precision medicine oncology company involved in the discovery and development of targeted therapeutics, announced on Monday that it has named Darrin M Beaupre, M.D., PhD as its new chief medical officer, effective 21 November 2022.

Dr Beaupre has served as the chief medical officer and head of Research and Development in Oncology at BioSplice Therapeutics, senior vice president, head of Early Oncology Development and Clinical Research at Pfizer, Inc, vice president, head of Early Development and Immunotherapy at Pharmacyclics (Abbvie) and medical director at Amgen and assistant professor at the H. Lee Moffitt Cancer Center and Research Institute.

Yujiro S Hata, president and chief executive officer of IDEAYA Biosciences, said, 'We are very excited to welcome Dr Beaupre to IDEAYA. He joins us as we target to expand our clinical pipeline in the first half of 2023 to include potentially five clinical trials across four programs – darovasertib (PKC) in MUM and UM, IDE397 (MAT2A) in MTAP-deletion tumours, IDE161 (PARG) in HRD tumours and, in collaboration with GSK, our Pol Theta Helicase Inhibitor development candidate in HRD tumours. Dr Beaupre's deep clinical development and translational research experience will help us unlock the value of our growing clinical pipeline.'